The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Tsareva N.A.

NII pul'monologii FMBA Rossii, Moskva

Avdeev S.N.

I.M. Sechenov First Moscow State Medical University under the Ministry of Health of the Russia, Moscow, Russia, 119991;
Pulmonology Research Institute under the Federal Medical and Biological Agency of Russia, Moscow, Russia, 115682

Nekliudova G.V.

NII pul'monologii FMBA Rossii, Moskva

A patient with severe idiopathic pulmonary arterial hypertension: Is there a way out?

Authors:

Tsareva N.A., Avdeev S.N., Nekliudova G.V.

More about the authors

Journal: Therapeutic Archive. 2017;89(9): 100‑103

DOI: 10.17116/terarkh2017899100-103

Views: 874

Downloaded: 520

Download PDF (RU)
Contact the author
Table of contents

A PATIENT WITH SEVERE IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION: IS THERE A WAY OUT?
A PATIENT WITH SEVERE IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION: IS THERE A WAY OUT?

To cite this article:

Tsareva NA, Avdeev SN, Nekliudova GV. A patient with severe idiopathic pulmonary arterial hypertension: Is there a way out? Therapeutic Archive. 2017;89(9):100‑103. (In Russ.)
https://doi.org/10.17116/terarkh2017899100-103

МСФ на ЯМ
Close metadata
Recommended articles:
Effi­cacy of combined therapy of prurigo adultorum with application of temgicoluril anxiolytic. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):210-216

The paper considers a clinical example of current therapy for idiopathic pulmonary arterial hypertension in a female patient with its clinical deterioration. It shows the tactics of switching from one drug (bosentan) to others (macitentan) within in the same pathogenetic therapy group (endothelin receptor antagonists). The latest pulmonary hypertension classification (Nice, 2013) is presented. The current strategies of pathogenetic therapy for pulmonary hypertension are discussed.

Keywords:

idiopathic pulmonary arterial hypertension
combined therapy
riociguat
bosentan
macitentan

Authors:

Tsareva N.A.

NII pul'monologii FMBA Rossii, Moskva

Avdeev S.N.

I.M. Sechenov First Moscow State Medical University under the Ministry of Health of the Russia, Moscow, Russia, 119991;
Pulmonology Research Institute under the Federal Medical and Biological Agency of Russia, Moscow, Russia, 115682

Nekliudova G.V.

NII pul'monologii FMBA Rossii, Moskva

List of references:

  1. Humbert M, Souza R, Galie N, McLaughlin V, Simonneau G, Rubin L. Pulmonary arterial hypertension: bridging the present to the future. Eur Respir Rev. 2012;21:126,267-270.
  2. Galie N, Rubin LJ et al. Pulmonary Arterial Hypertension: epidemiology, pathobiology, assessment, and therapy. J Am Coll Cardiology. 2004;12:5S-12S.
  3. Barst RJ, McGoon M, Torbicki A et al. Diagnosis and differential assessment of pulmonary artrerial hypertension. J Am Coll Cardiol. 2004;43(Suppl.12):40S-47S.
  4. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation. 2006;114:1417-1431.
  5. Galie N, Hoeper MM, Humbert M et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009;34:1219-1263.
  6. Galie N, Hoeper M, Torbicki A, Vachiery JL et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493-2537.
  7. Kovacs G, Avian A, Olschewski A, Olschewski H. Zero reference level for right heart catheterization. Eur Respir J. 2013;42:1586-1594.
  8. Hoeper MM, Huscher D, Ghofrani HA et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol. 2013;168:871-880.
  9. Fishman AP, McGoon MD, Chazova IE, Fedullo PF, Kneussel M, Peacock AJ et al. Diagnosis and assessment of pulmonary hypertension. In: Rich S, editor. Primary pulmonary hypertension: executive summary from the world 1998. Accessed March 4, 2002.
  10. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Europ Heart J. 2004;25:2243-2278.
  11. McLaughlin VV, Archer SL, Badesch DB et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009;119:2250-229.
  12. Humbert M, Sitbon O, Yaici A et al. Survival in incident and prevalent cohort of patients with pulmonary arterial hypertension. Eur Respir J. 2010;36:549-555.
  13. Nickel N, Golpon H, Greer M et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2012;39:589-596.
  14. Galie N, Humbert M, Vachiery JL et al. 2015 ECS/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2016;37:67-119.
  15. Benza RL, Miller DP, Gomberg-Maitland M et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010; 122:164-172.
  16. Simonneau G, Gatzolis G, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25,Suppl):D35-41.
  17. Galie N, Manes A. New treatment strategies for pulmonary arterial hypertension: hopes or hypes? J Am Coll Cardiol. 2013;62:1101-1102.
  18. Galie N, Manes A, Negro L et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J. 2009;30:2493-537.
  19. Simonneau G, Galie N, Hoeper MM et al. An interim analysis of long-term outcome in patients treated with bosentan in the double-blind or open-label extension of the EARLY trial. Am J Respir Crit Care Med. 2011;183:A5886. McLaughlin VV, Oudiz RJ, Frost A et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174:1257-1263.
  20. McLaughlin VV, Oudiz RJ, Frost A et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174:1257-1263.
  21. Ghofrani HA, Rose F, Schermuly RT et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol. 2003;42:158.
  22. Michelakis E, Tymchak W, Lien D et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 2002;105:2398.
  23. Gruenig N et al. Combination treatment of pulmonary arterial hypertension with bosentan and sildenafil. Clin Pharmacology. 2009;49:1343-1352.
  24. Tsareva N, Avdeev S, Nekludova G. Sequential combination therapy for patient with idiopathic pulmonary arterial hypertension (clinical case). Cardiology. 2016;56:3. (In Russ.).
  25. Evgenov OV, Pacher P, Schmidt PM et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov. 2006;5:755-768.
  26. Schermuly RT, Stasch JP, Pullamsetti SS et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J. 2008;32:881-891.
  27. Stasch JP, Evgenov OV. Soluble guanylate cyclase stimulators in pulmonary hypertension. Handb Exp Pharmacol. 2013;218:279-313.
  28. Ghofrani HA, Grimminger F. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy. Eur Respir Rev. 2009;18:35-41.
  29. Ghofrani HA, Galie N, Grimminger F et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369:330-340.
  30. Pulido T, Adzerikho I, Channick RN et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369:809-818.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.